

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number  
**WO 2005/009956 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 207/16,**  
**A61K 31/401, A61P 43/00**

Park, NC 27709 (US). **RANDHAWA, Amarjit, Sab**  
[CA/US]; GlaxoSmithKline, Five Moore Drive, PO Box  
13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number:  
**PCT/US2004/023263**

(74) Agents: **LEVY, David, J. et al.**; GlaxoSmithKline, Five  
Moore Drive, PO Box 13398, Research Triangle Park, NC  
27709 (US).

(22) International Filing Date: **19 July 2004 (19.07.2004)**

(25) Filing Language: **English**

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(26) Publication Language: **English**

(30) Priority Data:  
**60/488,902** **21 July 2003 (21.07.2003)** **US**

(71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]; One Franklin Plaza, Philadelphia, PA 19101  
(US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **IGO, David, H.**  
[US/US]; GlaxoSmithKline, Five Moore Drive, PO Box  
13398, Research Triangle Park, NC 27709 (US). **JOHN-**  
**SON, Paul, R.** [US/US]; GlaxoSmithKline, Five Moore  
Drive, PO Box 13398, Research Triangle Park, NC 27709  
(US). **PATTERSON, Daniel, E.** [US/US]; GlaxoSmithK-  
line, Five Moore Drive, PO Box 13398, Research Triangle

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **(2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECAR-**  
**BONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF**

**Powder X-ray diffraction pattern of anhydrous form 1 tosylate salt**



(57) Abstract: The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-β-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt.

WO 2005/009956 A1



**Published:**

- with international search report
- with amended claims

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*